(Q40873818)

24 September 2017

1 reference

title

Mifepristone (RU486): a review (English)

1 reference

24 September 2017

1 reference

D K Mahajan

1

1 reference

24 September 2017

S N London

series ordinal

2

1 reference

24 September 2017

language of work or name

English

0 references

publication date

1 December 1997

1 reference

24 September 2017

published in

Fertility and Sterility

1 reference

24 September 2017

volume

68

1 reference

24 September 2017

issue

6

1 reference

24 September 2017

page(s)

967-976

1 reference

Regio and stereospecific synthesis of 11 beta-substituted 19-norsteroids. Influence of 11 beta-substitution on progesterone receptor affinity - (1)

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Characterization and colocalization of steroid binding and dimerization activities in the mouse estrogen receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Differences in the binding mechanism of RU486 and progesterone to the progesterone receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Pharmacokinetics and metabolism of RU 486

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Plasma levels of antiprogestin RU 486 following oral administration to non-pregnant and early pregnant women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Metabolism and serum binding of RU 486 in women after various single doses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Transplacental passage of mifepristone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

The placental transfer of mifepristone (RU 486) during the second trimester and its influence upon maternal and fetal steroid concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Effects of the antiprogesterone RU486 in the early follicular phase of the menstrual cycle.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Effects of the antiprogesterone RU 486 in normal women. II. Administration in the late follicular phase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Acute effects of progesterone and the antiprogestin RU 486 on gonadotropin secretion in the follicular phase of the menstrual cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

The antiprogestin RU486 delays the midcycle gonadotropin surge and ovulation in gonadotropin-releasing hormone-induced cycles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Termination of very early pregnancy by RU 486--an antiprogestational compound

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Termination of early gestation with the anti-progestin steroid RU 486: medium versus low dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Preliminary results with the antiprogestational compound RU-486 (mifepristone) for interruption of early pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Early abortion with a single dose of the antiprogestin RU-486.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Therapeutic abortion in early pregnancy with antiprogestogen RU486 alone or in combination with prostaglandin analogue (gemeprost)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Induction of therapeutic abortion in early pregnancy with mifepristone in combination with prostaglandin pessary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

The efficacy of oral Mifepristone (RU 38,486) with a prostaglandin E1 analog vaginal pessary for the termination of early pregnancy: Complications and patient acceptability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Medical abortion in women of less than or equal to 56 days amenorrhoea: a comparison between gemeprost (a PGE1 analogue) alone and mifepristone and gemeprost

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Pregnancy termination with mifepristone and gemeprost: a multicenter comparison between repeated doses and a single dose of mifepristone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Mifepristone (RU 486) and second-trimester termination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Efficacy of the antiprogestin mifepristone (RU 486) prior to prostaglandin termination of pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Pretreatment with mifepristone (RU 486) reduces interval between prostaglandin administration and expulsion in second trimester abortion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

The use of mifepristone prior to prostaglandin-induced mid-trimester abortion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

The use of antiprogestin (RU 486) for termination of second trimester pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

A study of gemeprost alone, dilapan or mifepristone in combination with gemeprost for the termination of second trimester pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Cervical ripening of the rat in dependence on endocrine milieu; effects of antigestagens.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Effects of RU486 on the Interstitial Collagenase in the Process of Cervical Ripening in the Pregnant Rat

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Progesterone antagonist (RU 486) for cervical dilation, labor induction, and delivery in monkeys: effectiveness in combination with oxytocin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

The effects of RU-38486 on cervical ripening. Clinical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

The use of mifepristone (RU 486) for cervical preparation in first trimester pregnancy termination by vacuum aspiration. World Health Organization. Task Force on Post-ovulatory Methods for Fertility Regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Effect of mifepristone on dilatation of the pregnant and non-pregnant cervix.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Postcoital contraception with mifepristone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Alternative treatments in oral postcoital contraception: interim results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Comparison of Yuzpe regimen, danazol, and mifepristone (RU486) in oral postcoital contraception

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Contraception with mifepristone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Effects of the antiprogesterone steroid RU 486 during midluteal phase in normal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Immunohistochemical analysis of estrogen and progesterone receptors in endometriosis: comparison with normal endometrium during the menstrual cycle and the effect of medical therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Cell proliferation in normal human breast ducts, fibroadenomas, and other ductal hyperplasias measured by nuclear labeling with tritiated thymidine. Effects of menstrual phase, age, and oral contraceptive hormones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

A correlative morphologic study of human breast and endometrium in the menstrual cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Antiprogestins inhibit growth and stimulate differentiation in the normal mammary gland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Treatment of breast cancer with different antiprogestins: preclinical and clinical studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Role of antiprogestational therapy for meningiomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Symptomatic relief of meningioma by buserelin maintenance therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Treatment of unresectable meningiomas with the antiprogesterone agent mifepristone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Mifepristone (RU 486) treatment of meningiomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Successful mifepristone treatment of recurrent, inoperable meningioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

Pre-operative cervical preparation before first trimester vacuum aspiration: a randomized controlled comparison between gemeprost and mifepristone (RU 486)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Endocrine responses to long-term administration of the antiprogesterone RU486 in patients with pelvic endometriosis

1 reference

https://api.crossref.org/works/10.1016%2FS0015-0282%2897%2900189-1

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0015-0282(97)00189-1

1 reference

24 September 2017

1 reference